Thursday, June 01, 2023
Bayer and Cedilla Therapeutics have recently entered into an exclusive licence agreement to collaborate on the development and commercialisation of Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors.
As part of the agreement, Cedilla will receive an initial payment and may also be eligible for additional milestone payments linked to the progress of development and commercialisation efforts. In addition, Cedilla will receive royalties from any drugs derived from their technology that Bayer successfully brings to market.
Cyclin E, a binding partner of Cyclin Dependant Kinase 2 (CDK2), plays a crucial role in the development of certain cancers through overexpression or genetic activation. This unique approach allows for precise targeting of the cyclin E/CDK2 complex, specifically in a patient population with a high unmet medical need.
By selectively inhibiting this complex, Cedilla's small molecules have the potential to offer enhanced safety and efficacy compared to existing standard-of-care treatments. This innovative method of action holds promise for addressing the underlying oncogenic processes and improving outcomes for patients in need of more effective therapeutic options.
